Lixisenatide (ELIXA trial), liraglutide (LEADER trial), subcutaneous semaglutide (SUSTAIN-6 trial), exenatide (EXSCEL trial), and dulaglutide (REWIND trial) were GLP-1 RA drugs evaluated for kidney outcomes in this meta-analysis [data for kidney events were not available for albiglutide (Harmony Outcomes) or oral semaglutide (PIONEER 6), so this analysis excluded the outcomes of these trials] [55]
Pharmaceutics 11:117
Such unregulated peptides have had low purity percentages, driven up poison control emergency calls, and been connected to some major adverse events and allergies
Review Date 1/28/2026 Updated by: Ramin Fathi, MD, FAAD, Director, Phoenix Surgical Dermatology Group, Phoenix, AZ
It helps restore moisture balance, improves skin smoothness, and supports the skin barrier without making the skin feel greasy
Storage: 20C